Skip to main content

Table 4 Mean density and diameter of myelinated axons and thickness of their myelin sheaths

From: Enhancement of musculocutaneous nerve reinnervation after vascular endothelial growth factor (VEGF) gene therapy

 

Mean density of myelinated axons/10,000 μm² (n ± SD)

Axonal diameter (μm ± SD)

Myelin sheath thickness (μm ± SD)

Intact MCN

138 ± 32

3.30 ± 1.23

1.20 ± 0.50

Plasmid phVEGF ETE

191 ± 46*†‡#

2.07 ± 1.20*†‡

0.80 ± 0.30*†‡

Plasmid ETE

335 ± 45*‡

1.72 ± 0.15*‡

0.80 ± 0.15*‡

Vehiculum ETE

110 ± 52

1.52 ± 0.71*

0.65 ± 0.25*

Plasmid phVEGF ETS

115 ± 40†‡

1.80 ± 0.75*†‡

0.75 ± 0.32*

Plasmid ETS

260 ± 25*‡

1.65 ± 0.15*‡

0.71 ± 0.15*

Vehiculum ETS

91 ± 40

1.45 ± 0.11*

0.70 ± 0.32*

  1. * indicates statistic significance (P < 0.05) when compared with intact.
  2. † indicates statistic significance (P < 0.05) when compared with plasmid.
  3. ‡ indicates statistic significance (P < 0.05) when compared with vehiculum.
  4. # indicates statistic significance (P < 0.05) when compared with plasmid VEGF ETS.
  5. Mean density and diameter of myelinated axons as well as thickness of the myelin sheaths in the MCN of intact rats and those with end-to-end (ETE) or end-to-side (ETS) neurorrhaphy after application of plasmid phVEGF, plasmid (control) and vehiculum. Six rats were used for each group.